View Financial HealthItem 9 Labs 배당 및 자사주 매입배당 기준 점검 0/6Item 9 Labs 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 25Item 9 Labs Corp. Declines Re-Election of Lisa Rejler as Board MemberItem 9 Labs Corp. announced that the Nomination Committee proposes that the Annual General Meeting shall re-elect the board members Peter Rejler, Jan Samuelsson, Patrik Boman, Peter Johansson and Susanne Blanke and that the General Meeting resolves on new election of Martina Rejler. The board member Lisa Rejler declines re-election, at the AGM to be held on April 24, 2025.공시 • Apr 11Item 9 Labs Corp., Annual General Meeting, May 16, 2024Item 9 Labs Corp., Annual General Meeting, May 16, 2024, at 14:00 Central European Standard Time. Location: Östra Hamngatan 52 Gothenburg Sweden Agenda: To consider Presentation of the annual financial report and the auditor's report, as well as the consolidated annual financial report, the consolidated auditor's report and the Board of Directors' report; to consider (a) the adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet as well as the Board of Directors report pursuant to Chapter 8, Section 53a of the Swedish Companies Act, (b) the disposition of the Company's funds according to the adopted balance sheet and (c) the discharge from liability for the members of the Board of Directors and the CEO; to consider the election of members of the Board of Directors and appointment of auditors and deputy auditors, if any; and to consider any other matters.공시 • Jul 23+ 1 more updateDouglas Bowden Resigned as Chairman of the Board of Directors of Item 9 Labs Corp, Effective July 18, 2023Douglas Bowden has resigned his positions as Chairman of the Board of Directors of Item 9 Labs Corp, effective July 18, 2023. The positions will be left vacant until further notice due to the receivership appointment.공시 • May 25Item 9 Labs Corp. Announces Management ChangesItem 9 Labs Corp. announced that Director Jeffrey Rassás has been appointed to Strategic Advisor and will be primarily driving investor & public relations as well as capital needs. Chris Wolven, current Chief Operating Officer, will now oversee all Company entities and operations and will be the primary Company-facing executive for Item 9 Labs Corp. Michael Keskey has resigned as Chief Legal Officer.공시 • May 23+ 1 more updateItem 9 Labs Corp. Announces CEO ChangesItem 9 Labs Corp. announced that on May 17, 2023, Mr. Michael Weinberger voluntarily resigned as Chief Executive Officer and member of the Board of Directors of the Company. On May 22, 2023, the Board appointed Mr. Douglas Bowden, age 63, as the Company’s Interim Chief Executive Officer. Mr. Bowden is currently the Chairman of the Company’s Board of Directors. The biography for Mr. Bowden is set forth below: Mr. Bowden started his career in the electronics industry, working in a successful family run business, which he purchased with his brother and ran for nearly 20 years. This tech company's success was based on signal processing and monitoring providing hardware and software for broadcasters during the high definition revolution. Bowden sold his business in 2009 and in 2013, Mr. Bowden and his son started Viridis Group, a real estate company centered on residential remodeling, multifamily and commercial real estate development in Colorado and Arizona. Through this venture they gained experience in real estate acquisition, design, project and construction management, leasing, finance and sales. Viridis Group has recently adopted the name Bowden Investment Group. Mr. Bowden attended the University of South Dakota where he studied business. Mr. Bowden is co-founder of Viridis Group, dba Bowden Investment Group, a strategic partner of the Company.공시 • May 16Item 9 Labs Corp. announced delayed 10-Q filingOn 05/15/2023, Item 9 Labs Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 11Item 9 Labs Releases Latest Limited Edition One-Gram Rosin-Infused Pre-RollsItem 9 Labs announced the latest release of its limited edition one-gram rosin-infused pre-rolls in participating Arizona dispensaries. The product release follows a successful initial test run in December 2022 that immediately sold out after being stocked in local dispensaries and generated extremely positive customer and budtender feedback on the product quality. The demand for solventless cannabis products in Arizona has continued to grow since the start of the state's adult-use cannabis market, especially in the concentrate and vape categories. The niche sector provides a consistent, high quality and fuller expression of the various cannabinoids and terpenes that the cannabis plant has to offer. Cannabis data firm BDSA analyzed product data from the past year and noted that the growing rosin category is making a significant mark among many mature markets in the evolving industry, counting single to double-digit growth in sales from 2021 to 2022. Item 9 Labs' addition of rosin-infused pre therolls bolsters its already extensive product lineup of connoisseur grade pre-rolls, featuring one-gram pre-rolls crafted with its award-winning flower and infused with live resin sugar, live resin badder or crumble concentrates. According to BDSA's most recent market research, Item 9 Labs ranked No. 3 in Arizona's one-gram infused pre-roll category for February 2023, capturing 8.5% market share. Overall, the state generated $4.16 million in infused pre-rolls that month. Being sold in over 65% of Arizona's dispensaries, Item 9 Labs is recognized as one of the top 10 leading cannabis brands in the state. The rosin-infused pre -infused pre-rolls are sold at participating Botanica, JARS and Nature's Medicines locations, among other dispensaries throughout Phoenix.공시 • Dec 30Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/29/2022, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Dec 09Item 9 Labs Corp. Announces Management PromotionsItem 9 Labs Corp. announced promotion of Mark Busch, Senior Vice President of Corporate Development, Cory Carter, Senior Vice President of Cultivation and Jayne Levy Senior Vice President of Communications. Mark Busch is One of the first hires on the Unity Rd. brand, Busch joined in 2018, pre-dating Item 9 Labs Corp.'s acquisition of Unity Rd.'s franchisor, OCG Inc. in 2021. He is responsible for overseeing merger and acquisition strategy and activities. He has led the team through acquisitions of multiple dispensaries and most recently, has been spearheading the Company's approaching acquisition of Sessions. Carter joined OCG Inc. in 2019 and took over all Item 9 Labs Corp. cultivation operations upon acquisition close. He is lead on all production, manufacturing and packaging of the Company's award-winning Item 9 Labs cannabis products, including managing a team of 50-plus and aiding in the continued development of the Company's cultivation and lab site in Coolidge, Ariz. Levy has been with Unity Rd. since the cannabis franchise's inception in 2018. She plays an integral role in the Company with a hand in all facets of communications – spearheading internal and corporate communications, investor relations, public relations and beyond.공시 • Dec 01+ 1 more updateItem 9 Labs Corp. Announces Resignation of Andrew Bowden as DirectorOn November 23, 2022, Mr. Andrew Bowden voluntarily resigned as Chief Executive Officer and member of the Board of Directors of Item 9 Labs Corp. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The Company is appreciative of Mr. Bowden’s years of service to the Company as a director and Chief Executive Officer.공시 • Aug 04Item 9 Labs Corp. to Report Q3, 2022 Results on Aug 15, 2022Item 9 Labs Corp. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 15, 2022공시 • Jun 05Item 9 Labs Corp Announces Resignation of Jeffrey Rassas as the Chief Strategy OfficerOn June 1, 2022, Mr. Jeffrey Rassas resigned, effective immediately, as the Chief Strategy Officer of Item 9 Labs Corp. (the Company") and the Company's management accepted Mr. Rassas' resignation on June 1, 2022. Mr. Rassas' resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, practices, or otherwise. Mr. Rassas will remain on the Company's board of directors and will continue working with the Company in a consulting role.공시 • May 26Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million.Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million on May 18, 2022. As per the terms of the transaction, Item 9 Labs shall pay $12.8 million plus the earnout payments of $4.1 million of common stock 12 months following the closing date and $4.1 million common stock 24 months following the closing date subject to post-closing adjustments. Item 9 Labs Corp. shall pay a termination fee of $0.54 million to the sellers. The transaction is subject to customary closing conditions including Item 9 Labs receiving financing sufficient to complete the transaction and Sessions Cannabis shall have a minimum cash balance of $0.1 million. Frank Robinson and Jeffrey Mikelberg of Cassels Brock & Blackwell LLP acted as legal advisors to the sellers and Francesco Gucciardo and Gary Volman of Aird & Berlis LLP acted as legal advisor to Item 9 Labs Corp.공시 • Mar 06Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC.Item 9 Labs Corp. (OTCPK:INLB) agreed to acquire Certain Assets of Nebrina Adams County LLC for $2 million on October 6, 2021. The total purchase price will be payable as follows: (i) Upon conditional approvals of the change of ownership from state and local licensing authorities concerning the transfer of ownership of the Licenses from Seller to Buyer, Buyer shall deposit into an escrow account One Million US Dollars. ii) At the Closing, Buyer and Company shall execute and deliver to Seller an unsecured promissory note with a principal amount of Two Hundred Thousand US Dollars ($200,000.00), with an interest rate of five percent (5%) per annum simple interest, for a term of eighteen (18) full months commencing on the Closing Date, and payable in six (6) installments commencing on the last day of each three (3) month period following the Closing Date (the " Note " or " Promissory Note" ) until paid in full; and (iii) Buyer shall issue to the Seller Three Hundred Thousand (300,000) shares of PubCo's restricted common shares of the Company. The Shares shall be subject to a leak out agreement. Closing shall be contingent upon the unconditional approval by MED and the Local Licensing Authority of the Transactions. Jean Gonnell of Gonnell Law acted as legal advisor to Nebrina. Zuber Lawler & Del Duca LLP acted as legal advisor to Item 9. Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC on March 4, 2022.공시 • Mar 04Item 9 Labs Corp. Appoints Shane Evans to Its Board of DirectorsItem 9 Labs Corp. announced that Shane Evans, founder of Massage Heights, has been appointed to its Board of Directors.공시 • Feb 03Item 9 Labs Corp. Announces Resignation of Ronald L. Miller, Jr. from the Board of DirectorsOn January 25, 2022, Mr. Ronald L. Miller, Jr. resigned, effective immediately, from the board of directors of Item 9 Labs Corp. and the board accepted Mr. Miller’s resignation on January 26, 2022. Mr. Miller’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, practices, or otherwise. The Company is appreciative of Mr. Miller’s decade of service to the Company as a director. Mr. Miller will continue working with the Company in a financial consulting role.공시 • Dec 31Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/30/2021, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Dec 30Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/29/2020, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Sep 26Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million.Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million on February 27, 2020. Under the terms of the transaction, Item 9 Labs Corp. will issue 30 million restricted shares as consideration to acquire 52.22 million shares of OCG Inc. resulting in an exchange ratio of 0.575 shares of Item 9 Labs Corp. for each share of OCG Inc. Upon closing, OCG Inc. will become a wholly-owned direct subsidiary of Item 9 Labs Corp. Upon closing of the transaction, OCG Inc. may nominate, and Item 9 Labs Corp. agrees to appoint, two persons designated by OCG Inc. to Item 9 Labs Corp.’s Board of Directors. The transaction is subject to the adoption of the agreement by the requisite vote of the stockholders of OCG Inc. and Item 9 Labs Corp., approval of the issuance of shares of Item 9 Labs Corp. as merger consideration, an appropriate level and Director and Officers Liability Insurance being in place, financing contingency that Item 9 Labs Corp. must raise approximately $2 million and delivery by OCG Inc. of copies of a lock up and leak out agreement. The Board of Directors of Item 9 Labs Corp. has approved the agreement and the transactions contemplated hereby. The transaction is expected to closing in early July 2020. The transaction is expected to close near the Item 9 Labs’s fiscal year end of September 30, 2020. Michael Weiner and David Mangum of Dorsey & Whitney LLP acted as legal advisors for OCG, Inc. Jessica M. Lockett of Horwitz +Armstrong acted as legal advisor for Item 9 Labs Corp.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 INLB 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: INLB 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Item 9 Labs 배당 수익률 vs 시장INLB의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (INLB)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (INLB) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 INLB 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 INLB 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 INLB 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: INLB 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 23:18종가2026/05/11 00:00수익2023/06/30연간 수익2022/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Item 9 Labs Corp.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Joseph GomesNOBLE Capital Markets, Inc.
공시 • Mar 25Item 9 Labs Corp. Declines Re-Election of Lisa Rejler as Board MemberItem 9 Labs Corp. announced that the Nomination Committee proposes that the Annual General Meeting shall re-elect the board members Peter Rejler, Jan Samuelsson, Patrik Boman, Peter Johansson and Susanne Blanke and that the General Meeting resolves on new election of Martina Rejler. The board member Lisa Rejler declines re-election, at the AGM to be held on April 24, 2025.
공시 • Apr 11Item 9 Labs Corp., Annual General Meeting, May 16, 2024Item 9 Labs Corp., Annual General Meeting, May 16, 2024, at 14:00 Central European Standard Time. Location: Östra Hamngatan 52 Gothenburg Sweden Agenda: To consider Presentation of the annual financial report and the auditor's report, as well as the consolidated annual financial report, the consolidated auditor's report and the Board of Directors' report; to consider (a) the adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet as well as the Board of Directors report pursuant to Chapter 8, Section 53a of the Swedish Companies Act, (b) the disposition of the Company's funds according to the adopted balance sheet and (c) the discharge from liability for the members of the Board of Directors and the CEO; to consider the election of members of the Board of Directors and appointment of auditors and deputy auditors, if any; and to consider any other matters.
공시 • Jul 23+ 1 more updateDouglas Bowden Resigned as Chairman of the Board of Directors of Item 9 Labs Corp, Effective July 18, 2023Douglas Bowden has resigned his positions as Chairman of the Board of Directors of Item 9 Labs Corp, effective July 18, 2023. The positions will be left vacant until further notice due to the receivership appointment.
공시 • May 25Item 9 Labs Corp. Announces Management ChangesItem 9 Labs Corp. announced that Director Jeffrey Rassás has been appointed to Strategic Advisor and will be primarily driving investor & public relations as well as capital needs. Chris Wolven, current Chief Operating Officer, will now oversee all Company entities and operations and will be the primary Company-facing executive for Item 9 Labs Corp. Michael Keskey has resigned as Chief Legal Officer.
공시 • May 23+ 1 more updateItem 9 Labs Corp. Announces CEO ChangesItem 9 Labs Corp. announced that on May 17, 2023, Mr. Michael Weinberger voluntarily resigned as Chief Executive Officer and member of the Board of Directors of the Company. On May 22, 2023, the Board appointed Mr. Douglas Bowden, age 63, as the Company’s Interim Chief Executive Officer. Mr. Bowden is currently the Chairman of the Company’s Board of Directors. The biography for Mr. Bowden is set forth below: Mr. Bowden started his career in the electronics industry, working in a successful family run business, which he purchased with his brother and ran for nearly 20 years. This tech company's success was based on signal processing and monitoring providing hardware and software for broadcasters during the high definition revolution. Bowden sold his business in 2009 and in 2013, Mr. Bowden and his son started Viridis Group, a real estate company centered on residential remodeling, multifamily and commercial real estate development in Colorado and Arizona. Through this venture they gained experience in real estate acquisition, design, project and construction management, leasing, finance and sales. Viridis Group has recently adopted the name Bowden Investment Group. Mr. Bowden attended the University of South Dakota where he studied business. Mr. Bowden is co-founder of Viridis Group, dba Bowden Investment Group, a strategic partner of the Company.
공시 • May 16Item 9 Labs Corp. announced delayed 10-Q filingOn 05/15/2023, Item 9 Labs Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 11Item 9 Labs Releases Latest Limited Edition One-Gram Rosin-Infused Pre-RollsItem 9 Labs announced the latest release of its limited edition one-gram rosin-infused pre-rolls in participating Arizona dispensaries. The product release follows a successful initial test run in December 2022 that immediately sold out after being stocked in local dispensaries and generated extremely positive customer and budtender feedback on the product quality. The demand for solventless cannabis products in Arizona has continued to grow since the start of the state's adult-use cannabis market, especially in the concentrate and vape categories. The niche sector provides a consistent, high quality and fuller expression of the various cannabinoids and terpenes that the cannabis plant has to offer. Cannabis data firm BDSA analyzed product data from the past year and noted that the growing rosin category is making a significant mark among many mature markets in the evolving industry, counting single to double-digit growth in sales from 2021 to 2022. Item 9 Labs' addition of rosin-infused pre therolls bolsters its already extensive product lineup of connoisseur grade pre-rolls, featuring one-gram pre-rolls crafted with its award-winning flower and infused with live resin sugar, live resin badder or crumble concentrates. According to BDSA's most recent market research, Item 9 Labs ranked No. 3 in Arizona's one-gram infused pre-roll category for February 2023, capturing 8.5% market share. Overall, the state generated $4.16 million in infused pre-rolls that month. Being sold in over 65% of Arizona's dispensaries, Item 9 Labs is recognized as one of the top 10 leading cannabis brands in the state. The rosin-infused pre -infused pre-rolls are sold at participating Botanica, JARS and Nature's Medicines locations, among other dispensaries throughout Phoenix.
공시 • Dec 30Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/29/2022, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Dec 09Item 9 Labs Corp. Announces Management PromotionsItem 9 Labs Corp. announced promotion of Mark Busch, Senior Vice President of Corporate Development, Cory Carter, Senior Vice President of Cultivation and Jayne Levy Senior Vice President of Communications. Mark Busch is One of the first hires on the Unity Rd. brand, Busch joined in 2018, pre-dating Item 9 Labs Corp.'s acquisition of Unity Rd.'s franchisor, OCG Inc. in 2021. He is responsible for overseeing merger and acquisition strategy and activities. He has led the team through acquisitions of multiple dispensaries and most recently, has been spearheading the Company's approaching acquisition of Sessions. Carter joined OCG Inc. in 2019 and took over all Item 9 Labs Corp. cultivation operations upon acquisition close. He is lead on all production, manufacturing and packaging of the Company's award-winning Item 9 Labs cannabis products, including managing a team of 50-plus and aiding in the continued development of the Company's cultivation and lab site in Coolidge, Ariz. Levy has been with Unity Rd. since the cannabis franchise's inception in 2018. She plays an integral role in the Company with a hand in all facets of communications – spearheading internal and corporate communications, investor relations, public relations and beyond.
공시 • Dec 01+ 1 more updateItem 9 Labs Corp. Announces Resignation of Andrew Bowden as DirectorOn November 23, 2022, Mr. Andrew Bowden voluntarily resigned as Chief Executive Officer and member of the Board of Directors of Item 9 Labs Corp. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The Company is appreciative of Mr. Bowden’s years of service to the Company as a director and Chief Executive Officer.
공시 • Aug 04Item 9 Labs Corp. to Report Q3, 2022 Results on Aug 15, 2022Item 9 Labs Corp. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 15, 2022
공시 • Jun 05Item 9 Labs Corp Announces Resignation of Jeffrey Rassas as the Chief Strategy OfficerOn June 1, 2022, Mr. Jeffrey Rassas resigned, effective immediately, as the Chief Strategy Officer of Item 9 Labs Corp. (the Company") and the Company's management accepted Mr. Rassas' resignation on June 1, 2022. Mr. Rassas' resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, practices, or otherwise. Mr. Rassas will remain on the Company's board of directors and will continue working with the Company in a consulting role.
공시 • May 26Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million.Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million on May 18, 2022. As per the terms of the transaction, Item 9 Labs shall pay $12.8 million plus the earnout payments of $4.1 million of common stock 12 months following the closing date and $4.1 million common stock 24 months following the closing date subject to post-closing adjustments. Item 9 Labs Corp. shall pay a termination fee of $0.54 million to the sellers. The transaction is subject to customary closing conditions including Item 9 Labs receiving financing sufficient to complete the transaction and Sessions Cannabis shall have a minimum cash balance of $0.1 million. Frank Robinson and Jeffrey Mikelberg of Cassels Brock & Blackwell LLP acted as legal advisors to the sellers and Francesco Gucciardo and Gary Volman of Aird & Berlis LLP acted as legal advisor to Item 9 Labs Corp.
공시 • Mar 06Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC.Item 9 Labs Corp. (OTCPK:INLB) agreed to acquire Certain Assets of Nebrina Adams County LLC for $2 million on October 6, 2021. The total purchase price will be payable as follows: (i) Upon conditional approvals of the change of ownership from state and local licensing authorities concerning the transfer of ownership of the Licenses from Seller to Buyer, Buyer shall deposit into an escrow account One Million US Dollars. ii) At the Closing, Buyer and Company shall execute and deliver to Seller an unsecured promissory note with a principal amount of Two Hundred Thousand US Dollars ($200,000.00), with an interest rate of five percent (5%) per annum simple interest, for a term of eighteen (18) full months commencing on the Closing Date, and payable in six (6) installments commencing on the last day of each three (3) month period following the Closing Date (the " Note " or " Promissory Note" ) until paid in full; and (iii) Buyer shall issue to the Seller Three Hundred Thousand (300,000) shares of PubCo's restricted common shares of the Company. The Shares shall be subject to a leak out agreement. Closing shall be contingent upon the unconditional approval by MED and the Local Licensing Authority of the Transactions. Jean Gonnell of Gonnell Law acted as legal advisor to Nebrina. Zuber Lawler & Del Duca LLP acted as legal advisor to Item 9. Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC on March 4, 2022.
공시 • Mar 04Item 9 Labs Corp. Appoints Shane Evans to Its Board of DirectorsItem 9 Labs Corp. announced that Shane Evans, founder of Massage Heights, has been appointed to its Board of Directors.
공시 • Feb 03Item 9 Labs Corp. Announces Resignation of Ronald L. Miller, Jr. from the Board of DirectorsOn January 25, 2022, Mr. Ronald L. Miller, Jr. resigned, effective immediately, from the board of directors of Item 9 Labs Corp. and the board accepted Mr. Miller’s resignation on January 26, 2022. Mr. Miller’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, practices, or otherwise. The Company is appreciative of Mr. Miller’s decade of service to the Company as a director. Mr. Miller will continue working with the Company in a financial consulting role.
공시 • Dec 31Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/30/2021, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Dec 30Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/29/2020, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Sep 26Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million.Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million on February 27, 2020. Under the terms of the transaction, Item 9 Labs Corp. will issue 30 million restricted shares as consideration to acquire 52.22 million shares of OCG Inc. resulting in an exchange ratio of 0.575 shares of Item 9 Labs Corp. for each share of OCG Inc. Upon closing, OCG Inc. will become a wholly-owned direct subsidiary of Item 9 Labs Corp. Upon closing of the transaction, OCG Inc. may nominate, and Item 9 Labs Corp. agrees to appoint, two persons designated by OCG Inc. to Item 9 Labs Corp.’s Board of Directors. The transaction is subject to the adoption of the agreement by the requisite vote of the stockholders of OCG Inc. and Item 9 Labs Corp., approval of the issuance of shares of Item 9 Labs Corp. as merger consideration, an appropriate level and Director and Officers Liability Insurance being in place, financing contingency that Item 9 Labs Corp. must raise approximately $2 million and delivery by OCG Inc. of copies of a lock up and leak out agreement. The Board of Directors of Item 9 Labs Corp. has approved the agreement and the transactions contemplated hereby. The transaction is expected to closing in early July 2020. The transaction is expected to close near the Item 9 Labs’s fiscal year end of September 30, 2020. Michael Weiner and David Mangum of Dorsey & Whitney LLP acted as legal advisors for OCG, Inc. Jessica M. Lockett of Horwitz +Armstrong acted as legal advisor for Item 9 Labs Corp.